MedTrace Logo

Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients

NCT01874860 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-12-01

No results posted yet for this study

Summary

The purpose of this study is to determine if using preventive treatments such as Doxycycline (an anti-biotic) capsules, sunscreen with SPF 30, Hydrocortisone 1% cream and a moisturizer will help to reduce the incidence and severity of the skin rash associated with Cetuximab (Erbitux®) when compared to receiving standard care for the treatment of skin rash.

Conditions

Interventions

DRUG

Doxycycline

Doxycycline capsule, 100 mg, taken twice daily

DRUG

Hydrocortisone 1% cream

Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)

OTHER

Sunscreen

Applied to exposed skin areas at least 30 minutes before going outdoors each morning.

OTHER

Moisturizer

Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen

DRUG

Clindamycin

Recommended for daily use if rash returns (Topical cream)

DRUG

Medrol-dose pack (Steroid)

Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.

Sponsors & Collaborators

  • James Graham Brown Cancer Center

    collaborator OTHER

  • University of Louisville

    lead OTHER

Principal Investigators

  • Rebecca A. Redman, MD · James Graham Brown Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2018-07-31
Completion
2018-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01874860 on ClinicalTrials.gov